Pharmacology, Toxicology and Pharmaceutical Science
Atrial Fibrillation
100%
Amiodarone
50%
Heart Arrhythmia
46%
Antiarrhythmic Agent
40%
Anticoagulant Agent
40%
Antiarrhythmic Drug
40%
Warfarin
37%
Drug-Drug Interaction
33%
Direct Oral Anticoagulant
29%
Etacizine
26%
Recurrent Disease
26%
Beta Adrenergic Receptor Blocking Agent
26%
Rivaroxaban
20%
Dabigatran
20%
Persistent Atrial Fibrillation
20%
Aldosterone
20%
Angiotensin
20%
Renin
20%
Congestive Heart Failure
19%
Recurrence Risk
15%
Proton Pump Inhibitor
15%
Omega-3 Fatty Acid
14%
Brain Infarction
13%
Propafenone
13%
Coronary Artery Disease
13%
Thromboembolism
12%
Mineralocorticoid Antagonist
11%
Combination Therapy
9%
Comorbidity
9%
Drug Interaction
8%
Anticoagulation Therapy
8%
Drug Concentration
6%
Pharmacodynamics
6%
Diabetes Mellitus
6%
Cardiovascular Risk
6%
Dyslipidemia
6%
Heart Death
6%
Prevalence
6%
Cerebrovascular Accident
6%
Heart Infarction
6%
Pharmacokinetics
6%
Antiinflammatory Agent
6%
Antithrombotic Therapy
6%
Monotherapy
6%
Acetylsalicylic Acid
6%
Prospective Study
6%
Drug Choice
6%
Antivitamin K
5%
Medicine and Dentistry
Atrial Fibrillation
40%
Cardioversion
40%
Recurrent Disease
24%
Recurrence Risk
22%
Persistent Atrial Fibrillation
20%
Cardiac Dysrhythmia
20%
Renin Angiotensin Aldosterone System
20%
Antiarrhythmic Activity
20%
Cardiovascular System
20%
Mineralocorticoid Antagonist
11%
Sinus Rhythm
10%
Apoplexy
6%
Transient Ischemic Attack
6%
Biochemistry, Genetics and Molecular Biology
Drug Interaction
20%
Drug Concentration
10%
Pharmacodynamics
10%
Proton Pump
10%
Laboratory Test
10%
Blood Plasma
10%
High Risk Population
10%
Dyslipidemia
10%
Cardiac Dysrhythmia
10%
Pharmacokinetics
10%
Amiodarone
10%
Quantitative Technique
10%
Rivaroxaban
10%
Comorbidity
10%